Targeted Management of Infected Wounds and Purulent Lesions

This preparation is considered relevant in situations where patients experience skin injuries complicated by bacterial infection. The supportive benefit helps address symptom clusters related to microbial presence and contributes to easing the overall symptom load associated with compromised tissues. The antibiotic component provides symptomatic support needed to manage the infection. It is considered relevant in conditions such as purulent wounds, infected burns, trophic ulcers, and pressure ulcers (bedsores).

“This preparation is applied to help ease the symptomatic burden of persistent microbial contamination and contributes to the improvement of tissue repair.”

Easing Local Inflammation and Promoting Stability

The medication is often relevant when symptoms are associated with acute or episodic changes, which are often marked by the presence of pus and necrotic material. For patients managing these conditions, the preparation may assist with maintaining functional stability in the affected area, supporting them during episodes of heightened discomfort. This generally contributes to easing the overall symptom load and helps improve day-to-day comfort during symptomatic periods.

---

Quick Fact: Relief for Inflammatory Symptoms

This preparation is relevant for managing conditions that present with local symptoms related to inflammatory or irritative states alongside bacterial involvement. It is used in areas where short-term symptom management is appropriate and contributes to the improvement of tissue repair.

---

Regulatory References

1. NIH StatPearls Chloramphenicol overview

Eligibility Map: Who can and cannot use Levomekolio tepalas — Official Regulatory Information

Eligibility Scope

Category	Official Regulatory Statement
Populations Allowed	Use is permitted for adults and children from 3 years of age.
Populations Contraindicated	Patients with known hypersensitivity to Chloramphenicol, Methyluracil, or any excipients.
Age-Related Rules	Contraindicated in children under 3 years of age, setting the mandatory minimum age threshold for use.
Condition-Specific Rules	Contraindicated for individuals with specific dermatological conditions, including Psoriasis, Eczema, and Fungal skin lesions.
Systemic Restrictions	Non-eligible status for patients with Acute Porphyria or a personal/family history of blood dyscrasias, including aplastic anemia.
Pregnancy and Lactation	Conditional use status, permitted only if the anticipated benefit to the mother is determined to outweigh the potential risk to the fetus or child.

Eligibility Classifications (High-Level)

Eligibility Severity Classification: Absolute Contraindication; Restricted Population; Conditional Use.

Connection to the overall eligibility profile The official regulatory profile for this medicine defines eligible populations through a distinct minimum age threshold and a series of absolute contraindications. Eligibility is strictly denied to those with prior sensitivity to components and those diagnosed with specific systemic or skin comorbidities. Conditional use is imposed for pregnant and breastfeeding individuals.

The topical product Levomekolio tepalas contains the active substance chloramphenicol, an antibiotic whose systemic absorption, even from skin application, may lead to documented drug interactions. These interactions are primarily mediated by the cytochrome P450 enzyme system in the liver.

Potential Drug Interactions

Interacting Product Category	Specific Examples (where noted)	Interaction Mechanism
Enzyme Inducers	Phenobarbital, Rifampicin, Phenylbutazone, Nitrofurans	May increase the metabolism of chloramphenicol, potentially reducing its concentration and therapeutic effect.
CYP450 Substrates	Tolbutamide (antidiabetic), Diphenylhydantoin (anticonvulsant)	Chloramphenicol may inhibit the activity of the CYP450 enzyme, potentially decreasing the metabolism and increasing the blood levels of these co-administered medications.

Interaction-Related Restrictions

Regulatory documents advise against the concomitant use of this product with certain types of therapeutic agents due to concerns about increased systemic effects or complications. Therefore, simultaneous use with cytostatics (anti-cancer agents), sulfonamides (antibiotics), or in combination with radiotherapy should be avoided. Consult a healthcare professional before combining the ointment with any other systemic or topical treatment.

How Levomekolio tepalas Works

The dual action of this preparation relies on the complementary physiological effects produced by its two active components.

Molecular Inhibition of Bacterial Growth

The Chloramphenicol component acts by inhibiting bacterial translation (protein synthesis) within susceptible cells. It functions as a reversible inhibitor, binding specifically to the 50S ribosomal subunit to prevent the formation of peptide bonds at the peptidyl transferase center. This molecular interaction arrests the growth and reproduction of bacteria, resulting in a reduction of the local microbial load at the site of application.

Stimulating Host Cellular Regeneration

Methyluracil, the regenerative component, engages the pyrimidine salvage pathway in local host cells. Acting as a structural precursor, it supports the acceleration of nucleic acid (DNA/RNA) synthesis, which boosts the proliferation rate of fibroblasts and epithelial cells. This process accelerates the natural formation of granular tissue and epithelial coverage, contributing to the physiological process of new cell generation for tissue integrity.

The administration of Levomekolio tepalas is based on a defined set of principles, establishing its use as a short-course, external (topical) application only. The official formulation is an ointment containing 7.5 mg/ g of Chloramphenicol and 40 mg/ g of Methyluracil.

The usage pattern mandates daily dressing changes, with the application technique contingent on the lesion type. For surface wounds, the ointment is applied by impregnating sterile gauze napkins which are then used to fill or cover the affected area. When treating deep or purulent cavities, a specific preparation requirement is followed: the ointment is first preheated to 35-36 C before being introduced through a drainage system.

The dosage is constrained by defined limits, specifying that the daily quantity used should not exceed 3 g of the ointment when addressing large wound surfaces. The medication is intended for adults and children over 3 years of age. Application is maintained until the area is completely cleansed of purulent-necrotic material, but the treatment course is limited to a short duration, typically 5 to 7 days. Continued use beyond four days is often constrained due to the hyperosmolar properties of the base, necessitating a transition to alternative tissue-promoting agents as part of the overall protocol.

Research evidence / Overview of studies for Levomekolio tepalas

Evidence for use in Acute Purulent Wounds

Research has examined this preparation for use in conditions characterized by fluctuating or episodic manifestations, particularly acute purulent and postoperative soft tissue wounds. The evidence base includes systematic reviews, comparative clinical studies, and limited randomized controlled trials (RCTs). Researchers monitored study groups to track outcomes related to systemic or functional imbalance, such as the time required for wound cleansing and the process of new tissue formation.

In comparative settings, the ointment was often used in research exploring short-term symptom changes against other investigational preparations. Researchers documented measurements related to the time required for wound cleansing and epithelialization in the comparator groups receiving this ointment. Systematic reviews described patterns observed in the studies of topical chloramphenicol, noting that the antibiotic-containing ointment was observed in some studies to be associated with a non-statistically significant reduction in infection rates compared to control groups.

Evidence for use in Localized Otorhinolaryngological Infections

The preparation was studied for localized infections, such as acute otitis externa and nasal furuncle, in specialized clinical settings. These small-scale clinical studies applied in studies examining patient-reported experiences in mixed populations of both children and adults. Researchers monitored the bacteriological profiles to assess the sensitivity of isolated pathogens to the Chloramphenicol component. One non-comparative clinical study described that positive clinical changes were documented in a high percentage of the studied patient group.

Long-Term Outcomes and Follow-up Durations

The research currently available primarily focuses on studies conducted during periods of increased symptom activity and short-term changes, specifically evaluating the initial phases of wound cleansing. Because follow-up durations were limited in most published trials—often only spanning 5 to 14 days—long-term effects are not fully established. The existing evidence provides context but not individual predictions for the acute application.

Limitations, Evidence Gaps, and Research Uncertainty

A key constraint is the evidence quality varies across studies, with a noted paucity of high-quality clinical data in the form of large, definitive RCTs. The preparation was frequently used as a reference in research, meaning it is often not the main focus of investigative research. Therefore, comparative evidence is lacking in several areas, and subgroup findings are uncertain. Research provides context but not individual predictions, and the findings describe group patterns, not personal outcomes under the specific conditions studied.

Key Studies & References

1. A systematic review and meta-analysis on the use of prophylactic topical antibiotics for the prevention of uncomplicated wound infections

Common questions about Levomekolio tepalas (FAQ)

Q: Is Levomekolio tepalas the same as an antibiotic ointment?

A: According to official product information, Levomekolio tepalas is classified as a combined drug with dual action. It contains Chloramphenicol for its antimicrobial effect and Methyluracil for a reparative effect to help support cell regeneration. This combination suggests it is utilized for both infection control and tissue support, setting it apart from a pure antibiotic ointment.

Q: What is the main difference between Levomekolio tepalas and simple petroleum jelly?

A: Levomekolio tepalas uses a specialized Macrogol/Polyethylene Glycol base which is hydrophilic (water-miscible) and has osmotic activity to draw fluid (exudate) from the wound. This base is also non-occlusive (it does not seal the skin). In contrast, simple petroleum jelly is oil-based, and creates an occlusive, sealing layer on the skin.

Q: Does Levomekolio tepalas contain steroids or hormones?

A: The official composition of Levomekolio tepalas only lists Chloramphenicol and Methyluracil as active ingredients. The product is formally classified as an Amphenicol Antibiotic and a Tissue Regeneration Stimulant. Steroids or hormones are not listed as components in the product's official regulatory documentation.

Q: Can Levomekolio tepalas be used on a fresh cut or scraped knee?

A: The official indication for this product is for purulent wounds, infected burns, and wounds in the initial phase of the healing process. Official regulatory documents focus its indication on these scenarios; its use for completely fresh, uninfected cuts is not specified.

Q: How quickly do people generally expect to see a change after starting Levomekolio tepalas?

A: The regulatory documents describe the intended use as a short-term treatment course, typically lasting about 4 days, but potentially up to 5 to 7 days. Dressings are generally recommended to be performed daily until the wound is completely clean. This suggests that its intended therapeutic action is short-term.

Q: Can Levomekolio tepalas be applied to areas near the eye?

A: Official instructions and warnings emphasize that the ointment is for external use only. Specifically, warnings state that the ointment should not be allowed to make contact with the mucous membrane of the eyes.

Q: Is Levomekolio tepalas appropriate for minor burns?

A: The regulatory indication for use is specifically the treatment of infected burns. Official information does not differentiate use based on burn severity (minor versus severe).

Q: Why do some people use Levomekolio tepalas for skin irritations that aren't injuries?

A: The official purpose of the medicine is related to wound care and infected areas. The official eligibility profile lists specific non-injury skin conditions, such as psoriasis, eczema, and fungal lesions, as contraindications for use.

Q: What is the consistency of Levomekolio tepalas like?

A: Levomekolio tepalas is manufactured as an ointment (tepalas). According to official specifications, its physical properties are described by its color, which is typically white or white with a yellowish tinge.

Q: Does the ointment have a strong smell?

A: While the official product description notes the ointment's color, the smell is not typically addressed. However, the Macrogol excipient base, which is the primary non-active component, is generally described in pharmacological literature as being odorless.

Q: Can I use Levomekolio tepalas if I have sensitive skin?

A: Official regulatory documents list common local adverse reactions that may occur upon use. These reactions include a burning sensation, itching, skin rashes, and dermatitis. These documented reactions are listed in official safety information as potential concerns.

Q: Are there different concentrations of Levomekolio tepalas available?

A: Official product documentation specifies a single standard composition for the active ingredients: 7.5 mg of Chloramphenicol and 40 mg of Methyluracil per gram of ointment. The existence of different strengths is not noted in the main regulatory documents for this specific product.

Q: What happens if I accidentally use Levomekolio tepalas past its expiration date?

A: The regulatory document sets a specific shelf-life, typically 2 years from the date of manufacture, to ensure the stated integrity of the product. Using a product past its expiration date may compromise its quality and stated effectiveness, consistent with general pharmaceutical practice.

Q: Is Levomekolio tepalas described as working only on the surface of the skin?

A: The product base facilitates component penetration into the tissues, but regulatory documents note that the exact degree of systemic absorption is not established. Caution related to absorption is noted in the safety warnings.

Q: Are there specific materials or clothing that Levomekolio tepalas might stain?

A: The ointment's base is a Macrogol/Polyethylene Glycol formula, which is considered water-miscible. Because of this property, the product can typically be easily washed off with water, which suggests a reduced risk of permanent staining on clothing or materials.

Q: What does 'for external use only' mean for Levomekolio tepalas?

A: This is a safety instruction indicating that the product should not be swallowed and is only intended for application on the skin, away from mucous membranes.

Q: What is the purpose of the non-active ingredients in Levomekolio tepalas?

A: The non-active base of the ointment is made of Macrogols (polyethylene glycols). This base is specialized to adsorb wound exudate (fluid released from the wound) and to potentiate the activity of the active ingredients, Chloramphenicol and Methyluracil.

Q: Is it normal to feel a warming or cooling sensation after applying?

A: The official product information lists common local reactions that may be experienced upon application. These include a burning sensation and itching. Any other sensation, such as warming or cooling, is not explicitly documented as a standard or expected effect.

Q: Does Levomekolio tepalas interact with natural or herbal remedies applied to the skin?

A: Regulatory restrictions advise caution and consultation before combining the ointment with any other systemic or topical treatment. This general restriction extends to the use of the product with other topical treatments, including natural or herbal remedies.

Q: Is Levomekolio tepalas described as having a moisturizing effect?

A: The Macrogol base is described as having osmotic activity which helps draw out fluid, rather than providing a moisturizing effect.

Q: What is the difference in purpose between Levomekolio tepalas and a typical antiseptic cream?

A: Levomekolio tepalas is categorized as having a dual purpose: it provides antimicrobial action for infection control and reparative action (tissue regeneration) from the Methyluracil component. A typical antiseptic cream usually focuses only on disinfection or microbial control.

Q: What official guidance is available for accidental swallowing of a small amount?

A: If the product is swallowed, official guidance is to seek assistance from a doctor or the nearest emergency department.

Q: Can I use Levomekolio tepalas if I am taking other oral medications?

A: Regulatory documents advise against the simultaneous use of this product with specific systemic agents, including cytostatics (anti-cancer agents), sulfonamides (antibiotics), or in combination with radiotherapy. This is due to the potential for systemic absorption and interaction.

Q: Do official documents mention anything about using Levomekolio tepalas on facial skin?

A: Official warnings address the most sensitive areas of the face by stating that the ointment should not be allowed to make contact with the mucous membrane of the eyes. Any other use on the face should be guided by this safety principle.

Official Storage and Disposal Instructions

Requirement Type	Official Labeled Condition
Temperature	Store at a temperature not higher than 25 C
Freezing/Handling	Do not allow the ointment to freeze
Packaging	Must be stored in its original packaging
Shelf-Life	Labeled expiration is 2 years from the manufacture date
Child Safety	Keep out of the sight and reach of children
Disposal	Follow local regulatory guidelines for discarding unused or expired product

All storage and handling must conform strictly to these labeled requirements to maintain product integrity and safety. The maximum temperature of 25 C and the prohibition against freezing are critical for stability. The product must remain inaccessible to children. Disposal of the medicine should align with local regulatory methods for non-hazardous pharmaceutical waste.